New Severe Asthma Rx Gets Green Light

Cinqair (reslizumab), from Teva, approved to treat severe asthma

(RxWiki News) The US Food and Drug Administration (FDA) has approved Cinqair (reslizumab) to manage severe asthma.

Cinqair was approved as a maintenance treatment for severe asthma in patients 18 years and older and is to be given with other asthma medications. The FDA approved it for those with a history of severe asthma attacks despite receiving other asthma medicines.

Cinqair, which is marketed by Teva Pharmaceuticals, works to lower levels of a type of blood cell involved in the development of asthma, according to the FDA.

Based on trial data, when compared to patients who received a placebo, patients who received Cinqair had fewer asthma attacks and a longer time to their first asthma attack. In addition, patients who received Cinqair saw a significant improvement in lung function.

Asthma is a chronic lung disease that causes inflammation in the airways of the lungs.

Cinqair is administered into the vein by a health care provider once every four weeks. The most common side effect of Cinqair is throat pain.